Clinical Trials Sponsored by Debiopharm S.A.

Total 3233 results

Debiopharm International SA

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Astrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Spain, United States, Switzerland
Debiopharm International SA

Completed

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Neoplasms | Carcinoma, Non-Small-Cell Lung

Canada, Poland, Romania
Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
Debiopharm International SA

Completed

Study of Debio 1450 for Bacterial Skin Infections

Bacterial Infections

United States
Debiopharm International SA

Terminated

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Hepatitis C

United States
Debiopharm International SA

Completed

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Chronic Pain | Hepatitis C

United States, Belgium, Germany, Taiwan, Australia, France, Thailand, Puerto Rico, United Kingdom, Italy, India, Poland, Korea, Republic of, Canada
Debiopharm International SA

Completed

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

Hepatitis C | Liver Disease

Germany, Sweden, United Kingdom, Poland
Debiopharm International SA

Completed

A Single Dose Study of Debio 1450 in Healthy Subjects

Bacterial Infections

United States
Debiopharm International SA

Completed

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Lymphoma | Cancer | Solid Tumors | Malignancy

United States
Debiopharm International SA

Completed

A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects

Healthy Participants

United Kingdom
Debiopharm International SA

Completed

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Hepatitis C | Liver Disease

United States, France
Debiopharm International SA

Completed

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

Hepatitis C

Romania, Italy, Hungary, Taiwan, Turkey, Belgium, Spain, Germany, Australia, France, United States, United Kingdom, Poland, Puerto Rico
Debiopharm International SA

Terminated

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

Hepatitis C

United States, Germany, France, Spain, Italy, United Kingdom, Puerto Rico, Canada
Debiopharm International SA

Terminated

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Solid Tumors

France
Debiopharm International SA

Completed

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Chronic Hepatitis C

United States
Debiopharm International SA

Completed

Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

Healthy

United Kingdom
Debiopharm International SA

Completed

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Bacterial Infections

United States
Debiopharm International SA

Completed

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Neoplasms | Lymphoma | Cancer | Solid Tumors

France
Debiopharm International SA

Completed

Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients

Fibrosis | Inflammation | Pulmonary Fibrosis | Lung Disease | Acute Respiratory Distress Syndrome | Respiratory Distress Syndrome, Adult | Respiratory Disorders

France, Italy, Spain, Tunisia
Debiopharm International SA

Recruiting

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

Central Precocious Puberty

United States
Debiopharm International SA

Recruiting

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Small Cell Lung Cancer Recurrent

United States, Spain
Debiopharm International SA

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Cancer (ccRCC)

France, Australia
Debiopharm International SA

Recruiting

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Switzerland
Debiopharm International SA

Recruiting

Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Netherlands, Spain
Debiopharm International SA

Recruiting

Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

Bone or Joint Infection

United States, Ukraine, South Africa, Argentina
Debiopharm International SA

Active, not recruiting

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (OXTEND-01)

Acromegaly | GEP-NET

United Kingdom, France, Spain, Italy, Poland, Denmark, Germany, Israel
Debiopharm International SA

Completed

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (SMARTPLUS-106)

Solid Tumor

United States, Spain, France
Debiopharm International SA

Completed

Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial

Squamous Cell Carcinoma of the Head and Neck

France, Switzerland
Debiopharm International SA

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants

Healthy Volunteers

United Kingdom
Debiopharm International SA

Terminated

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Solid Tumours

Korea, Republic of, United States, Taiwan, Spain, Singapore
Debiopharm International SA

Completed

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

Bone Diseases, Infectious

United States
Debiopharm International SA

Completed

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Central Precocious Puberty

United States, Chile, Mexico
Debiopharm International SA

Completed

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

Hepatitis C

United States, Romania, Belgium, Germany, Hungary, Taiwan, Spain, Italy, Australia, France, Hong Kong, Thailand, Korea, Republic of, United Kingdom, Argentina, Russian Federation, Canada, Poland, Puerto Rico, Vietnam, Mexico
Debiopharm International SA

Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Hepatitis C

Romania, Italy, Belgium, Germany, Hungary, Taiwan, Spain, Australia, Hong Kong, Thailand, France, United States, United Kingdom, Turkey, Argentina, Russian Federation, India, Korea, Republic of, Vietnam, Poland, Mexico, Canada
Debiopharm International SA

Completed

Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects

Kidney Failure, Chronic

United States
Debiopharm International SA

Completed

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

Hepatic Insufficiency

United States
Debiopharm International SA

Completed

Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease (BRAINz)

Moderate Alzheimer's Disease

Australia, Canada, United Kingdom
Debiopharm International SA

Withdrawn

Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients

Heart Failure
Debiopharm International SA

Withdrawn

Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure

Heart Failure
Debiopharm International SA

Completed

Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

Prostatic Neoplasm

South Africa
Debiopharm International SA
Parexel

Completed

A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Chronic Hepatitis C

Spain, Belgium, Germany, Romania, France, Poland, Italy
Debiopharm International SA
Quintiles, Inc.

Completed

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Prostate Cancer

South Africa
Debiopharm International SA
Syneos Health

Terminated

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC] (HALO)

Non-small Cell Lung Cancer

Spain, France, United Kingdom
Repare Therapeutics
Debiopharm International SA

Recruiting

Study of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors (MYTHIC)

Advanced Solid Tumor

United States, Canada, Denmark
M.A. Med Alliance S.A.

Recruiting

SELUTION 4 De Novo Small Vessel IDE Trial

Coronary Artery Disease

United States
M.A. Med Alliance S.A.

Recruiting

The SELUTION DeNovo Study

Coronary Artery Disease

France, Czechia, United Kingdom, Germany, Italy, Switzerland, Austria, Finland, Poland
M.A. Med Alliance S.A.

Active, not recruiting

SAVE Trial - Use of the Selution Sirolimus Eluting Balloon for Dysfunctional AV accEss Treatment Indications (SAVE)

AV Fistula

Greece, Singapore
M.A. Med Alliance S.A.

Active, not recruiting

SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study (SUCCESS PTA)

Peripheral Artery Disease

Germany
M.A. Med Alliance S.A.

Completed

First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral Arteries

Patients With Peripheral Artery Disease in the SFA or PA

Germany
Ferrer Internacional S.A.
Histocell, S.L.

Recruiting

Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury (SPINE)

Acute Traumatic Spinal Cord Injury

Spain

3

Subscribe